Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

计划入组 30 人 · 首次发布于 2025 年 9 月 17 日

Reverse HER2-negative Immune Resistant Breast Cancer

计划入组 10 人 · 首次发布于 2024 年 12 月 12 日

Capecitabine in ER+/HER2-negative Breast Cancer

计划入组 15 人 · 首次发布于 2026 年 6 月 5 日

Sus scrofa stomach

anti-HER2 CAR macrophage therapy (metastatic stomach cancer)

Stomach Cancer(Nanjing Xinrui Regeneration)

Arvinas

United States

CENTER WEST CANCER

United States

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

China

PD-1 Inhibitor Label Restrictions May Impede Gastric Cancer R&D

FDA Reassesses Keytruda and Opdivo Labels Based on PD-L1 Biomarker Data in Gastric and Esophageal Cancers

Denosumab Shows Immunomodulatory Effects in HER2-Negative Early Breast Cancer